

Customer No. 22,852
Attorney Docket No. 03447.0017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Sylvie VAN DER WERF, et al.)
Application No.: Not Yet Assigned) Group Art Unit:
Filed: June 2, 2006) Examiner:
For: **NOVEL STRAIN OF SARS-)
ASSOCIATED)
CORONAVIRUS AND)
APPLICATIONS THEREOF)**

U.S. National Phase of International Application No. PCT/FR2004/003106

**MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08 and cited in the enclosed international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed with the above-referenced application.

The following is listed on the accompanying PTO/SB/08 and is in a non-English language:

CHE, ET AL., "Rapid and Efficient Preparation of Monoclonal Antibodies Against SARS-Associated Coronavirus Nucleocapsid Protein By Immunizing Mice". An English-language abstract of the document is enclosed.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please
charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 2, 2006

By: 
Ernest F. Chapman
Reg. No. 25,961

Enclosures
EFC/FPD/rac

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number		
			Filing Date		
			First Named Inventor		
			Art Unit		
			Examiner Name		
Sheet	1	of	1	Attorney Docket Number	03447.0017

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		DATABASE EMBL, XP002294758, Database accession no. AY278489, "EMBL Sequence Version Archive", pages 1-7, (April 22, 2003)	
		DATABASE EMBL, XP002294760, Database accession no. AY290752, "EMBL Sequence Version Archive", pages 1-2, (June 10, 2003)	
		DATABASE UNIPROT, XP002294761, Database accession no. P59595, pages 1-4, "Human Coronavirus", (October 10, 2003)	
		MARRA, ET AL., "The Genome Sequence of the SARS-Associated Coronavirus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, Vol. 300, no. 5624, pages 1399-1404, (May 30, 2003)	
		CHE, ET AL., "Rapid and Efficient Preparation of Monoclonal Antibodies Against SARS-Associated Coronavirus Nucleocapsid Protein By Immunizing Mice", DI YI JUNYI DAXUE XUEBAO - ACADEMIC JOURNAL OF FIRST MEDICAL COLLEGE OF PLA, GAIN KAN BIANJISHI, GUANGZHOU, CN, Vol. 23, No. 7, pages 640-642, (July 2003)	ABSTRACT
		WANG, ET AL., "Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WINSTON, US, Vol. 49, No. 12, pages 1989-1996, (November 13, 2003)	
		SHI, ET AL., "Diagnosis of Severe Acute Respiratory Syndrome (SARS) by Detection of SARS Coronavirus Nucleocapsid Antibodies in an Antigen-Capturing Enzyme-Linked Immunosorbent Assay", JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, Vol. 41, No. 12, pages 5781-5782, (December 2003)	
		LIU, ET AL., "The C-Terminal Portion of the Nucleocapsid Protein Demonstrates SARS-CoV Antigenicity", GENOMICS, PROTEOMICS AND BIOINFORMATICS, Vol. 1, No. 3, pages 193-197, (August 2003)	
		POON, ET AL., "Rapid Diagnosis of a Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WINSTON, US, Vol. 49, No. 6, Pt. 1, pages 953-955, (June 2003)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--